More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...
Verywell Health on MSN2d
The Surprising Role of Ketamine in Combatting Depression: A Pharmacist's InsightLearn more about how an anesthetic traditionally used for surgical procedures may help depression and what to expect during ...
The county reported its highest detainee death count in decades, including multiple suicides that reveal deep institutional ...
Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for standing by. At this time, all participants are in a listen-only mode. After the speakers’ presentation ...
If an insurance company has unfettered access to data from a biobank and discovers that there is a higher incidence of ...
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...
EMPOWER-1 and EMPOWER-2 Phase 2 clinical trials did not meet their primary endpoint Emraclidine was well-tolerated with an adverse event profile consistent with ...
Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...
A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback